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ABSTRACT: Glycosylation plays a myriad of roles in the immune system: Certain glycans can interact with specific immune
receptors to kickstart a pro-inflammatory response, whereas other glycans can do precisely the opposite and ameliorate the
immune response. Specific glycans and glycoforms can themselves become the targets of the adaptive immune system, leading
to potent antiglycan responses that can lead to the killing of altered self- or pathogenic species. This hydra-like set of roles
glycans play is of particular importance in cancer immunity, where it influences the anticancer immune response, likely playing
pivotal roles in tumor survival or clearance. The complexity of carbohydrate biology requires synthetic access to glycoproteins
and glycopeptides that harbor homogeneous glycans allowing the probing of these systems with high precision. One particular
complicating factor in this is that these synthetic structures are required to be as close to the native structures as possible, as
non-native linkages can themselves elicit immune responses. In this Review, we discuss examples and current strategies for the
synthesis of natively linked single glycoforms of peptides and proteins that have enabled researchers to gain new insights into
glycoimmunology, with a particular focus on the application of these reagents in cancer immunology.
■ INTRODUCTION
Mammalian cell biology cannot be understood without taking
post-translational protein glycosylation into account.1,2 This is
of particular relevance in the immune system, where glycans
play a myriad of roles at all stages of the immune response;
from the initial sensing of danger and the preservation of self-
cells, the homing of specific effector cell populations to the
right locations, to the resolution and dampening of the
immune response.3 These can be dependent on either broad
classes of glycan structure, or specific glycoforms on specific
sites of proteins.4,5
One archetypal example is that of sialyl LewisX-containing
glycoproteins. These carbohydrates can interact with the
selectin-family of lectins, which are upregulated on the
endothelial surface at sites of inflammation.6 In these proteins,
the underlying protein scaffold plays a minimal role in binding.
It is not until the upregulation of α-1,3-fucosyltransferase (Fuc-
TVII) expression (upon receiving an activating stimulus) that
the functional ligand sialyl LewisX is produced.7 The
introduction of this single monosaccharide converts immune
cell surface proteins, such as the P-selectin glycoprotein ligand-
1 (PSGL-1), into a glycoform capable of binding the immune
cell homing receptors, thereby orchestrating the key step of
effector cell mobilization of the immune response (Figure
1).8,9
Carbohydrates also play other important roles in the
initiation of the inflammatory response.10 They are the ligands
of a wide array of immune lectins, that upon ligation can
initiate the expression of pro-inflammatory cytokines, leading
to the initiation of an inflammatory response. For example, the
binding of β-1,3- and β-1,6-glucan structures by dectin-1, a
transmembrane receptor with a lectin-like carbohydrate
binding domain, is a key event in antifungal immunity.11
The ligation of this receptor to these, and other carbohydrate
ligands often found on unicellular pathogens, results in the
Syk-mediated activation of a variety of innate immune
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responses. This leads to the secretion of pro-inflammatory
cytokines, enhanced phagocytosis, and T-cell skewing to
antifungal Th1/Th17 phenotypes.12 Other members of this
family of carbohydrate pattern recognition receptors (PRRs)
include Mincle,13 Dectin-2,14 the mannose receptor,15 and
DC-SIGN,16 and all are of prime importance to the initiation
of antipathogenic immune responses.17
The interactions of carbohydrates with proteins can also
block or reduce inflammation. It has, for example, emerged
that changes in the heavy chain N-glycan (Situated on Asn297)
of IgG antibodies adjust the effector functions of the antibody
by fine-tuning, among other things, individual FcγR receptor
affinities.18,19 A simple fucosylation of the core pentasaccharide
of the glycan changes the affinity of the antibody toward Fc
receptors dramatically, thereby reducing the ability of an
antibody to recruit effector cells. In addition, the enzymatic
removal of sialic acids from the antennae of the complex-type
glycan can turn the properties of the antibodies from anti-
inflammatory to pro-inflammatory.20,21
Some of the aforementioned PRR-lectins can also serve as
immune-dampening lectins. For instance, ligation of mannosy-
lated lipoarabinomannan (ManLAM), a mycobacterial cell wall
component, to the dendritic cell (DC) C-type lectin receptor
DC-SIGN16 masks infection by hindering DC activation and
by stimulating secretion of the immunosuppressive cytokine
IL-10 in response to the otherwise highly immunogenic
bacterial compound LPS.22
Sialic acid binding immunoglobulin-type lectins (Siglecs) are
another important class of immune modulatory carbohydrate
receptors.23 These lectins, which are found on a wide variety of
immune cells, often have immunoreceptor tyrosine-based
inhibitory signaling motifs (ITIMs), which can initiate anti-
inflammatory signaling cascades.24 On B-cells, Siglec 2 (CD22)
can modulate the strength of B-cell receptor signaling,25 with
other Siglecs causing this immunosuppressive phenotype.23
This feature is, for example, exploited by Group B Streptococcus
aureus, which decorates its surface with ligands for siglec-9 to
prevent platelet-mediated killing.26
One interesting aspect of siglec-based immune modulation is
that tumors often exploit these receptors for their own immune
evasion. For example, in certain tumor types, siglec-9 was
shown to modulate the reactivity of a pool of CD8 positive
memory T-cells27 (CD8 positive T-cells recognize antigen in
MHC-I context to activate and then initiate killing of infected
or transformed target cells), and siglec-15 was shown to block
these T-cell responses.28 Therapeutic inhibition of the latter
showed a similar biological effect to clinical checkpoint
inhibitor therapy (e.g., anti-PD-L1).28 Even the broad removal
of sialic acids from the tumor surface was shown to enhance
antitumor responses.29
The recent discovery of the T cell immunoglobulin and
mucin-domain containing protein-3 (TIM-3) offers another
example of the immunomodulatory roles of glycans in the
tumor microenvironment. TIM-3 is expressed by various
immune cell types, and inhibition of this glycoprotein leads to
decreased tumor growth in preclinical models, probably
through the blockade of an immunomodulatory signal exerted
by this protein on cells ranging from DCs to tumor associated
macrophages, natural killer (NK)-cells, and T-cells.30 In
humans, tumor infiltrating CD8 positive T-cells in colorectal
cancer patients undergo apoptosis more readily if they express
TIM-3, and this was shown to be dependent on tumor
secretion of galectin-9 (which binds to the Tim-3 IgV domain
N-linked glycans) in vivo in a mouse model.31
The multiple roles of glycans as well as the heterogeneity of
naturally occurring glycans make the study of glycan−protein
interactions in the immune system complex. Although
analytical methods to determine the glycosylation sequences
and glycoform distribution of glycoproteins are now becoming
available,32,33 there is an acute need for access to single
glycoforms to study the immunological function of glyco-
proteins in vivo and to address whether specific single
glycoforms are required for optimal vaccination strategies.34
The aim of this Review is to illustrate the methodologies and
developments for synthesis of single glycoforms of immune-
relevant constructs and their use in strategies toward improved
treatments against cancer. We focus mainly on native linkages,
Figure 1. Carbohydrate−protein interactions play a myriad of roles in the immune system. They influence initial pattern recognition, leading to
immune activation, as well as the routing of immune cells in the body to immune suppressive effects. They can also be targets of antibody
responses, leading to clearance of specific glycans. All these events can affect others in the pathway either synergistically or detrimentally.
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as recent work has shown that non-native linkages can
themselves serve as (part of) the epitope in an adaptive
immune response and that the non-native linkages can alter the
processing that is required for a peptide to become capable of
T-cell activation.35,36
■ SYNTHESIS OF Tn, T, AND SIALYLATED
T(n)-ANTIGENS
One of the most pursued targets in the study of carbohydrate
immunity has arguably been the T/Tn-family of antigens.37
The mucin protein MUC-1, which is normally heavily O-
glycosylated, harbors a tandem repeat sequence (HGVTSA-
PDTRPAPGSTAPPA) and expressed at the site apical side of
mucous membranes. In adenocarcinoma, and certain hema-
topoietic cancers, it is expressed with truncated glycans on all
sides of the cell, resulting in humoral (i.e., antibody mediated)
response against the protein.38 The simplest of these truncated
glycans is a single N-acetylgalactosamine linked to a Ser/Thr-
residue, the so-called Tn-antigen, or Gal-β1-3-GalNAc-Ser/
Thr (T-antigen) and the 2,6- or 2,3-monosialylated variants of
these sugars (Figure 2A). These heavily truncated O-linked
glycans promote tumor survival by, e.g., binding the macro-
phage galactose lectin-1 (MGL-1) and various siglecs to
dampen the immune response. MGL-1 is, like other lectins,
expressed on tumor-associated macrophages,39 and its
presence is associated with poor prognosis and increased
cancer growth.40
Aberrantly glycosylated mucins were also found to illicit
strong humoral immune responses, with the glycan-containing
mucin-repeat regions serving as epitopes for both T- and B-
cells. This observation, taken together with the relatively easy
synthetic access to the glycans involved, has made MUC-1 a
prominent target for cancer immunotherapy, particularly for
vaccine strategies.38
Early attempts at exploiting this T- and B-cell recognition
potential in a vaccine, such as Tecemotide, which was a
liposome-anchored nonglycosylated MUC-1 tandem repeat
peptide, did not elicit protective immune responses in clinical
trial,41 nor did the first later-phase clinical trials of an α-2,6-
sialyl-Tn tandem repeat modified peptide conjugated to the
keyhole limpet hemocyanin carrier protein.42,43 This has not
deterred the further pursuit of MUC-1 as an immunotherapy
target, and virus-based vaccines such as the modified vaccinia
Ankara expressing MUC1 and IL-2,44 dendritic cell vacci-
nations,45 and chimaeric antigen receptor-T-cells (CAR T-
cells) targeting this aberrantly glycosylated protein,46,47 are in
clinical development.
Extensive synthetic effort has also gone into producing
tandem repeat (TR)-peptide based vaccines. For example, the
conjugation of the TR-peptides to other T-helper epitope
containing proteins, such as ovalbumin,48 or tetanus toxin,49
was reported by Kunz and co-workers to improve antibody
titers. This approach has also led to the development of
antibodies against aberrantly glycosylated MUC1 as diagnostic
tools,50 and preventive immunization in a humanized mouse
model expressing human MUC1 led to decreased growth rates
of MUC1 expressing tumors.51 Boons and co-workers
attempted to improve the vaccine through the direct
conjugation of toll-like receptor (TLR)-ligands and peptidic
T-helper epitopes to the TR-glycopeptides.52 To avoid carrier
and linker-induced immune suppression (leading to vaccine
rather than antigen neutralization),53−55 they made a single
polypeptide containing the glycosylated TR, as well as a T-
helper-epitope from the poliovirus type 1 capsid polypeptide
VP1103−115 (KLFAVWKITYKDT)
56 (Figure 2B). Antibody
titers were further improved when the immunological adjuvant
Pam3CysSK4, which efficiently activates antigen presenting
cells (APCs) via Toll-like receptor (TLR) 1/2,57,58 was also
attached covalently to the epitope. Surprisingly, the effect was
significantly higher than for coinjection of epitopes and
adjuvant, whereas exchange of this adjuvant for a TLR9
agonist turned out to be detrimental to the ability of the
vaccine to elicit the desired antibody response in mice.59
The results after the initial immunization with the vaccine
candidate (Figure 2B) were encouraging. The compound was
incorporated into phospholipid-based small unilamellar
vesicles (SUVs) and used for vaccination. After 4 vaccinations
at weekly intervals, anti-MUC-I IgG titers were very high. Only
low levels of antibodies directed toward the T-helper-epitope,
but robust CD8+ T-cell responses (and antitumor NK-cell
responses) were observed.60 The glycan was shown to be very
important for vaccination outcome. Both antibody titers,
humoral and cellular immunity assays, and tumor burden
assessment yielded significantly poorer results when the
vaccine candidate was used without the glycan, an observation
which has also since been made by Huang and co-workers.61
Figure 2. A. Chemical structures of the various truncated MUC-1
glycans. B. Chemical structure of the Boons tripartite vaccine.
Bioconjugate Chemistry Review
DOI: 10.1021/acs.bioconjchem.9b00588
Bioconjugate Chem. XXXX, XXX, XXX−XXX
C
However, both glycosylated and nonglycosylated peptides were
recognized by the produced antibodies. Although antibodies
that recognize glycans specifically are well-known,62 most
antibodies recognizing the glycosylated TR domain of MUC-1
exhibit increased binding to glycosylated epitopes without
actually recognizing the glycan.63,64 This effect has been
attributed to a more extended and antibody-accessible
conformation imposed on the peptide by the glycan,65 an
effect which has also been observed in other MUC-1-derived
motifs.66,67
CD8+ T-cell recognition also seems to be indirectly
mediated by the glycan, as T-cells from mice immunized
with the above tripartite vaccine were better at recognizing
both glycosylated and nonglycosylated peptides in vitro. This
observation might be explained by the peptide’s mode of
binding to MHC-I molecules on APCs, as the glycan belonging
to the synthetic MUC-1-epitope SAPDT(O-α-D-GalNAc)RPA
has been shown to be buried in the MHC groove rather than
being presented toward the T-cell receptor in a solvent
exposed position, thereby increasing the binding affinity of the
peptide toward the MHC-I molecule instead.65
Taken together with the observations that O-glycans can
influence MUC-1 antigen processing,68 but are not necessarily
removed in the process,69 it seems likely that the glycan has an
indirect role, promoting cross-presentation (presentation of
exogenous antigen in MHC-I context) of the glycosylated
peptide to CD8+ T-cells.70 Nevertheless, it is clear from the
above work that native glycans on a peptide vaccine can prove
highly beneficial for its efficacy. Further studies are still needed
to clarify some important complications associated with these
vaccines, such as tumor escape by immunoediting and
evasion.71,72
Figure 3. Native chemical ligation (NCL) and diselenide-selenoester ligation (DSL). A. Schematic representation of NCL, blue cylinder: peptide
thioester, red cylinder: N-terminal cysteinyl peptide. B. Schematic representation of DSL, blue cylinder: peptide selenoester, red cylinder: N-
terminal diselenide peptide. C. Design and synthesis of a self-adjuvating MUC-1 vaccine.
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The most recent clinical developments in the anti-MUC1
vaccine arena have focused on the multivalent delivery of the
TR-glycoepitopes,37,73 conjugating to other immune activating
lipids.74 It will be highly interesting to follow the progress of
such efforts and to see if these strategies will lead to new
exciting breakthroughs in the near future.
■ OTHER SYNTHETIC O-GLYCANS FOR IMMUNE
MODULATIONS
While the tumor associated aberrant O-glycosylation motifs of
the T and Tn types discussed in the previous section have
received the lion’s share of the attention from the synthetic
community, other glycosylation motifs have been investigated
as well. In one example, β-1,2-mannan containing peptides
conjugated to protein carriers were recently explored to induce
protection against infections from Candida albicans and other
fungi.75 Extensive efforts have also been put into the synthesis
of sialyl LewisX glycans as models of the natural human P-
selectin ligand P-selecting glycoprotein ligand-1 (PSGL-1).76
These might be able to inhibit the extravasation of
lymphocytes into sites of chronic or acute infection, and so
might alleviate symptoms of inflammation. Recent clinical trials
with the selectin-blocking glycomimetic Rivipansel have
provided interesting results for the treatment of vaso-occlusive
crises in patients suffering from sickle cell disease. However,
future trials will have to ascertain the significance of these
results in a statistical sense.77
The synthesis of sialyl LewisX, especially as part of
glycopeptide constructs, is made difficult by the nature of
the glycoside linkages involved. Specifically, the α2−3
sialylation needed and the easily acid-degradable fucosylation
pose large synthetic challenges. However, Wong and co-
workers elegantly showed that milligram-scale preparation of a
high-binding N-terminal fragment of PSGL-1 was possible
using a chemoenzymatic strategy.78,79
The biological evaluations of sialyl LewisX constructs seem
to be so far mostly limited to basic in vitro assays. As an
example, Kunz and co-workers prepared an N-linked version of
sialyl LewisX and successfully tested it as an inhibitor of E-
selectin binding to 32Dcl3 neutrophils.80 In another study,
they tested non-natively linked, multivalent glycoconjugates
containing sialyl LewisX or mixtures of the monosaccharides
contained in sialyl LewisX (sialic acid, galactose, and fucose) as
binders to endothelial cells and macrophages, and as inhibitors
of macrophage migration in vitro.81 However, as selectins are
an emerging target for treatment of excessive inflammation in
such diseases as metabolic syndrome and even psoriasis,82 we
hope that this clinical trial failure does not mark the end of this
field.
■ SYNTHESIS OF CHEMICALLY DEFINED
IMMUNE-RELEVANT GLYCOPEPTIDES AND
VACCINES VIA CHEMOSELECTIVE METHODS
One drawback of glycopeptide vaccines, despite being powerful
tools, is their low immunogenicity in vivo. A range of studies
showed that covalently attached adjuvants led to potent T-cell
responses,83 and to robust or even higher antibody titers, when
compared to separate application of adjuvant and vaccine.52,84
Thus, research has focused on methods to covalently attach
adjuvants to glycopeptide building blocks. One convenient way
to do this is to employ chemoselective ligation methods which
are orthogonal and give high selectivity during coupling
reactions.85 The chemoselective ligation methods to obtain
glycopeptides have been reviewed extensively,86−89 and will
not be discussed exhaustively in this article. Rather than this,
we will present a selection of chemoselective ligation methods
to prepare adjuvant containing glycopeptide based vaccines
with a special focus on O-glycans.
As discussed above, Boons and co-workers reported the first
successful synthesis of a self-adjuvating MUC1 cancer vaccine
(Figure 2B).52 To this end, they used a chemoselective ligation
method to conjugate the adjuvant to the peptide backbone,
namely, native chemical ligation (NCL). NCL is a chemo-
selective reaction between a C-terminal peptide α-thioester
and an N-terminal cysteinyl-peptide under aqueous conditions
with subsequent purification (Figure 3A).90 C-terminal peptide
α-thioesters and their precursors are compatible with standard
9-fluorenylmethoxycarbonyl (Fmoc) solid phase peptide
synthesis (SPPS) protocols. Already in 2006, Boons and
colleagues developed a method in which liposomes (consisting
of dodecylphosphocholine) were used to enhance the
solubilization of lipopeptides and assist the ligation of
lipophilic lipopeptide thioesters to their cysteinyl reaction
partners.91 This was the first demonstration of NCL in
glycopeptide vaccine design.
In the past decade, other NCL inspired chemoselective
conjugation methods were reported.92,93 One example worth
mentioning is the diselenide-selenoester ligation (DSL),
invented by Payne and co-workers.94,95 In this approach, the
researchers generate a selenoester at the C-terminus of
peptides, whereas the N-terminal selenocysteine dimer of a
second peptide enables a not yet fully explored ligation
mechanism resulting in the formation of a nascent peptide
bond upon deselenization (Figure 3B). This method is highly
efficient (quantitative conversion) and rapid (1−10 min).94,96
In the past decade, Payne and co-workers described the
synthesis of two and/or three component MUC 1 vaccines
(similar to Boons vaccines) using conventional fragment
condensation strategies.97−99 Recently, they expanded their
chemical toolbox with DSL to synthesize a Tn-antigen bearing
mucin tandem repeat peptide covalently linked to the TLR-2
agonist Pam2CysSK4 (adjuvant). In their approach, a
Pam2CysSK4 selenoester was synthesized using diphenyl
diselenide as a nucleophile (Figure 3C). The glycopeptide
with selenocysteine on its N-terminus could be synthesized
using standard SPPS protocols and the dimerization occurred
spontaneously. Next, the two peptide segments were ligated to
each other (2 min, quantitative conversion) with a yield of 62%
after purification. With the vaccine in hand, Payne and co-
workers performed in vivo experiments by injecting the vaccine
candidate subcutaneously into C57BL/6 mice. Adoptive
transfer of a mixture of control (PBS treated) or MUC-1
specific splenocytes into vaccinated mice resulted in a
significant increase in the MUC-1 specific CTL response.
Subsequently, antibody titers in sera from vaccinated mice
were assessed, and interestingly, vaccination led to high IgM
but not IgG titers. To improve the IgG titer, researchers mixed
the vaccine with the pan T-helper epitope PADRE. However,
the IgG titers did not increase. Instead, PADRE specific T-cells
secreted pro-inflammatory cytokines upon exposure to the self-
adjuvating vaccine and external PADRE in mixture, whereas
addition of PADRE without the vaccine did not cause the same
effect.
Another interesting approach to obtaining chemically well-
defined glycopeptide vaccines has been described by Kunz and
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co-workers, namely, the thioether ligation (Figure 4A).100 This
method relies on the nucleophilicity of sulfhydryl groups.
Halogenated acetamides such as iodoacetamide and bromoa-
cetamide have been shown to undergo nucleophilic sub-
stitution when reacted with cysteine or other reactive thiols.101
This technique has also been used for peptide ligation
strategies prior to the development of NCL.102
Kunz and colleagues used their thioether method for the
linkage of a lipidated adjuvant, Pam3CysSK4, to a mucine TR
peptide, which is attached to a T-helper epitope of the P2 or
P4 tetanus toxoid peptide (Figure 4B). In doing so, they
obtained a library of two- (without the Pam3Cys adjuvant) and
three-component vaccines, which could then be investigated
regarding their antibody titers and complement-dependent
cytotoxicity (CDC). The three-component vaccine containing
P2 Th epitope, Pam3Cys, and the TR peptide initiated an
immune response and exhibited high CDC even in the absence
of standard adjuvant usage.
These advances demonstrate the power of chemoselective
chemical ligation methods as tools for the synthesis of
glycopeptide vaccine constructs. With improved method-
ologies becoming available, so too are detailed studies of
glycopeptide vaccines with various adjuvants or helper epitopes
becoming increasingly feasible. Collaborative efforts between
chemistry and immunology research groups will likely benefit
from these new possibilities, spurring hope for the future
development of more effective vaccines.
■ SYNTHESIS OF SINGLE-GLYCOFORM N-GLYCAN
MODIFIED ANTIGENS
In comparison to the often short glycans found in aberrant O-
linked glycosylation, the synthesis of N-linked glycoproteins
and peptides involves larger sugars and a concomitant increase
in synthetic complexity.103,104 Their immunological evaluation
is therefore less developed than that of the T(n) antigen
family. N-Linked glycoproteins all share the same core motif,
but are modified with various terminal antennae. The synthesis
of single glycoforms for various applications has made great
inroads over the past few years, and the application to protein
and peptide total synthesis is also beginning to take shape.104
The most commonly used methods have focused on the use of
recombinant glycan-remodeling enzymes, total protein syn-
thesis, or the genetic engineering of the glycosylation
machinery of whole organisms to yield single glycoforms
upon recombinant expression.105 Here, we will give a short
overview on the above applications.
■ GLYCOPROTEIN TOTAL SYNTHESIS
The total synthesis of single glycoforms of glycoproteins
presents a phenomenal synthetic challenge, which has been
solved for very specific cases only. The milestone was the total
synthesis of a polyglycosylated single glycoform of eryth-
ropoietin by the group of Danishefsky.106,107 Since then, a few
other examples of natively linked glycoproteins have been
reported, which have been reviewed here.88,89,105,108,109 In the
context of this Reviewdue to their relevance as immune cell
signaling moietiesthe syntheses of cytokines bears mention-
ing. Cytokines are crucial for the modulation of inflammation
(both acute and chronic) via a complex mechanism.110 They
are secreted/expressed by immune cells as a response to
pathogens and other dangerous molecules.110 Their small size,
combined with often a single glycosylation site, has rendered
them attractive targets for glycoprotein total synthesis.
Interferon beta (IFN-β),108 the O-glycoprotein interleukin-2
(IL-2),111 granulocyte−macrophage colony-stimulating factor
(GM-CSF),112 and IL-6113 have all been synthesized using
semisynthetic strategies based on NCL methodology. To take
IFN-β as an example, Kajihara and co-workers synthesized it
carrying either a sialylated biantennary complex glycan, an
asialo-biantennary glycan, or no glycan, and its antitumor
activity was assessed highlighting a potential role for sialylation
in antitumor activity. The homogeneously sialylated variant
showed a slightly more pronounced antitumor effect, although
reasons for this effect remain unknown.114 In all, the chemical
synthesis of multiple single glycoforms of a single protein on a
scale sufficient for immunological evaluation remains a
herculean challenge.
Figure 4. Thioether ligation and its use in glyco-vaccine design. A. Schematic representation of thioether ligation, blue cylinder: C-terminal peptide
thiol, red cylinder: halogen-acetopeptide. B. Chemical structure of the Kunz-vaccine.
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■ CELLULAR GLYCOPROTEIN EXPRESSION FOR
PRODUCTION OF SINGLE GLYCOFORM
ANTIGENS
Single glycoform cell lines were first developed by the
company GlycoFi, who engineered the yeast strain Pichia
pastoris in such a manner that it produced single glycoforms of
glycoproteins,115 such as the antibody CD20.116 Recently, this
methodology has been applied to the production of single
glycoforms from Chinese hamster ovary (CHO)-cells, through
extensive engineering of the glycosylation machinery of these
cells.117,118 This approach, while in principle having the
potential to create single glycoforms of antigenic proteins has,
to the best of our knowledge, not yet been approached to
produce single glycoform cancer antigens. The complexity of
the approach must also not be underestimated; with the effort
required for each individual glycoform being mammoth-like.




Chemoenzymatic glycoprotein remodeling is the process by
which endo-β-N-acetylglucosaminidases (ENGases) are first
used to trim down a heterogeneous mixture of glycoforms to a
single N-acetylglucosaminyl (GlcNAc) residue (or an αFuc(1
→ 6)GlcNac if core fucosylation is present in the parent
glycoforms mixture) attached to asparagine.105 This single
GlcNAc can then be used as the handle for reintroducing a
homogeneous full-length native N-glycan using the same
enzyme class to catalyze the reverse reaction (Figure 5A). This
Figure 5. ENGase catalyzed glycosylation of proteins. A. Scheme of Man9GlcNAcylation of RNase B-GlcNAc via EndoA171A.121 B.
Cytomegalovirus pp65 peptide construct prepared and utilized by Fairbanks and co-workers to study antigen uptake and presentation.
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affords the desired single glycoform of the protein in question.
This type of methodology has been pioneered and reviewed by
the groups of Fairbanks119 and Wang,105 and today the
ENGases have been mutated to obtain optimal so-called
glycosynthases for the attachment of various different glycans
with almost no hydrolysis of the product obtained during the
enzymatic ligation reaction.119 Of all the above approaches to
obtain N-glycosylated peptides, this approach has been the
most extensively pursued in an immunological context.
Fairbanks and co-workers, for example, synthesized deriva-
tives of a 19-mer peptide derived from cytomegalovirus pp65
protein, containing a known cytotoxic T-cell epitope. Using
microwave-assisted SPPS, they synthesized the native peptide
as well as variants containing an N-linked GlcNAc on
asparagine residues within and adjacent to the T-cell epitope
(1a/b, Figure 5B).120 They then used the incorporated
GlcNAc residues as targets for ENGase-catalyzed glycosylation
using either truncated synthetic glycan oxazolines or full-length
high-mannose-type glycan oxazolines derived from soybean
flour. This approach yielded chemically defined peptides
(Figure 5B, 2a/b and 3a/b) containing single N-glycosylation
motifs linked via natural glycosidic bonds rather than by
nonhydrolyzable artificial covalent conjugation modes (Figure
5).
The authors went on to show that glycosylated peptides 2a/
b and 3a/b targeted antigen presenting cells (APCs),
expressing the mannose receptor (MR), significantly better
than the nonglycosylated parent peptide. Interestingly, in vitro
activation of peptide-specific CTL clones by APCs loaded with
the peptide constructs was completely absent when the peptide
was glycosylated inside the epitope (2b and 3b), but not when
the glycan was exclusively situated outside of the epitope (2a
and 3a). This result could indicate that the T-cell clones were
specific for peptides that were blocked by the presence of N-
glycans in the presented peptide, which were not (fully)
removed during antigen processing. This is in contrast to
previous experiments that do show their removal during the
processing of the peptides for MHC-loading.122,123 An
alternative reason could be that the process of glycan
introduction and removalwhich results in a net Asn to Asp
mutationchanged the binding properties of this peptide to
such an extent that the T-cell receptors of the clones used no
longer recognized this peptide. Indeed, we124,125 and others126
have shown recently that single-atom substitutions can be
enough to cause such an effect. Taken together, several factors
might play a role regarding N-glycans in antigen processing/
presentation, which should be investigated in more detail in
the future.
Recently, Wang and co-workers have also used a glycan
remodeling approach to produce a peptide-based vaccine. The
aim of this vaccine was to elicit an antibody response against
the 46 amino acid V3-domain of the HIV-1 ENV glycoprotein,
or a 33-mer truncation thereof. They synthesized a cyclic
version of this domain carrying a Man9-GlcNAc2-glycan,
which they further conjugated to a T-helper epitope and a
TLR-ligand.127 Upon vaccination, this construct potently
elicited antibodies against the glycan on the epitope,127
which could be further enhanced when the glycan was
displayed in a multivalent fashion.35
■ CONCLUDING REMARKS
The above examples serve to demonstrate that, although fully
glycosylated proteins are still hardly accessible via synthetic
chemistry, synthetic carbohydrate chemistry as of today does
provide ready access to some very important targets for
immunological and vaccine studies. The bespoke application of
these advances in technology may lead to critical findings not
only in basic research, but also in translational medicine, i.e., in
the development of novel vaccine technology.
The two most obvious caveats associated with the various
chemical methodologies discussed in this Review are that, on
one hand, the chemical expertise is still very much needed for
their successful application; and on the other hand, the
heterogeneity of tumors themselves complicate matters, with
individual tumors in individual patients likely showing high
glycan heterogeneity. However, the recent emergence of
patient-specific vaccine strategies may in future also be applied
here.61 We therefore strongly encourage the immunology and
carbohydrate communities to join forces to an extent that is
much larger than what is being done today. Such
collaborations will almost certainly lead to many exciting
discoveries which will greatly advance our fundamental as well
as translational scientific view of the immune system in action.
It is tempting to make the perhaps slightly provoking
prediction that some of these future discoveries will likely
alter the current mechanistic consensuses about glycoimmu-
nology, most of which have been established using non-
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